Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis

SJ Piddlesden, S Jiang, JL Levin, A Vincent… - Journal of …, 1996 - Elsevier
The loss of muscle function seen in myasthenia gravis and in the animal model of the
disease, experimental autoimmune myasthenia gravis (EAMG) is in part due to the activation
of complement by anti-acetylcholine receptor (AChR) antibodies at the motor end-plate. In
this study we describe the effects of a soluble recombinant form of human complement
receptor 1 (sCR1) on the development of clinical disease and receptor loss in EAMG
induced passively by administration of anti-AChR antibodies. Daily intraperitoneal injection …